Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company whose news flow centers on Alzheimer's disease drug development, pharmaceutical cannabinoids, and AI-enabled research. The company regularly reports updates on its lead asset, IGC-AD1, a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia, along with progress across its broader pipeline and AI platforms.
News about IGC Pharma often includes clinical trial milestones, such as enrollment progress and expansion of the CALMA study to new sites. For example, the company has highlighted reaching key enrollment thresholds and adding hybrid and virtual clinical sites like Dominion Medical Associates, part of Lightship's network, to improve access for patients in underserved and rural communities. These announcements provide insight into trial design, recruitment strategies, and geographic reach.
Investors and observers can also expect corporate and financial updates, including capital raises under an effective Form S-3 shelf registration statement, strategic divestitures of non-core assets, and changes to the company's fiscal year-end to align with the calendar year. SEC-reported events, such as registered direct offerings and asset sale closings, are frequently accompanied by press releases that explain how proceeds and transactions relate to IGC Pharma's clinical and research priorities.
Another recurring theme in IGC Pharma's news is AI and intellectual property developments. The company reports advances in its MINT-AD platform for Alzheimer's risk stratification and early detection, recognition from the National Institute on Aging for AI code quality, and new or allowed patents that expand its pharmaceutical cannabinoid portfolio, including microdose-based treatments for stuttering and Tourette's Syndrome.
In addition, IGC Pharma issues news on community and educational initiatives, such as sponsoring a caregiver-focused Alzheimer's book authored by neuropsychology experts. Together, these news items provide a view into the company's clinical progress, AI research, regulatory positioning, capital strategy, and engagement with the Alzheimer's community. Readers interested in IGC's stock and operations can use this news feed to follow trial updates, financing events, patent activity, and strategic decisions over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IGC Pharma, Inc. (NYSE American:IGC) has announced its participation in the Planet MicroCap Showcase: VEGAS 2023, scheduled for April 26, 2023, at 4:30 PM PDT. CEO Ram Mukunda and CFO Claudia Grimaldi will present and engage in a Q&A session following the presentation.
Investors can access the live presentation via webcast here. Registration for 1x1 investor meetings at the event is available here. The showcase aims to enhance awareness about MicroCap investments.
IGC Pharma focuses on cannabinoid-based formulations for various medical conditions, including Alzheimer’s disease and PMS. The company is currently conducting a Phase 2 clinical trial for its drug IGC-AD1 targeting agitation in Alzheimer’s patients.
Summary not available.
India Globalization Capital, Inc. (IGC) reported impressive third fiscal quarter 2023 results, with net revenue soaring 133% to $332,000 year-over-year, driven by its life science segment. The company is advancing its Phase 2 clinical trial for IGC-AD1, targeting agitation in dementia due to Alzheimer’s, expanding sites from four to up to 12 to enhance enrollment. The trial aims to involve 146 patients and establish efficacy over six weeks. R&D expenses rose to $806,000 due to increased trial activities, while SG&A expenses decreased to $1.5 million. Despite a net loss of $2.2 million, IGC remains optimistic about expanding its market presence and future FDA approval.
India Globalization Capital (NYSE American: IGC) announces an upcoming investor webinar featuring CEO Ram Mukunda and PFO Claudia Grimaldi on February 10, 2023, at 12:30 p.m. ET. They will discuss the Company’s Phase 2 trial for IGC-AD1, aimed at alleviating agitation in Alzheimer's patients. The trial involves 146 participants and is categorized as Phase 2B for safety and efficacy. IGC is focused on developing cannabinoid-based formulations for various conditions, including Alzheimer’s disease. The Company also markets wellness brands Holief and Sunday Seltzer.
India Globalization Capital (IGC) announced a no objection letter from Health Canada for its Phase 2 trial of IGC-AD1, targeting agitation in Alzheimer's disease. This approval allows the company to proceed with trials at multiple sites, including Canada and the U.S. CEO Ram Mukunda emphasized the importance of this milestone for patient enrollment and FDA approval. The formulation utilizes low doses of THC and has shown promise in early trials. Approximately 15 million people in North America and Europe are affected by Alzheimer's, highlighting the potential market impact.
India Globalization Capital, Inc. (IGC) has filed a life sciences presentation with the SEC on Form 8K, detailing its initiatives, particularly focusing on low-dose THC drug formulations and cannabinoid-based consumer products.
IGC's leading drug candidate, IGC-AD1, is in Phase 2 trials, targeting agitation in Alzheimer’s dementia. The company also offers CBD products for various health needs. Despite these advancements, the press release includes forward-looking statements subject to risks, such as regulatory challenges and market conditions that could impact product commercialization.